In the News

Share

Connect with us

Stay Informed.

Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
COVID-19: Information for Patients and Caregivers

We're here for you, and continue to provide cancer care to new and current patients. Learn about our response to COVID-19.

What you need to know

1663 News Items found
Microscopy image showing a quiescent cluster of lung adenocarcinoma tumor cells with low STING expression.
MSK Scientists Identify Potential New Strategy Against Metastasis

A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.
In the Clinic
Dr. Carol Aghajanian
For Advanced Endometrial Cancer, Chemotherapy Plus Immunotherapy Improves Outcomes

New research published in The New England Journal of Medicine finds adding the immunotherapy drug pembrolizumab (Keytruda®) to standard chemotherapy greatly improves outcomes in people with advanced endometrial cancer. The phase 3 study was overseen by MSK gynecologic medical oncologist Carol Aghajanian.
Finding
Michael Rosensweig with dog
Menin Inhibitors: Promising New Drug Treatment for Aggressive Leukemia

Results from the first-ever trial for a new class of leukemia drugs called menin inhibitors are encouraging.
A scientist pipetting in a lab
MSK Research Highlights, March 9, 2023

New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.
MSK physician-scientists Michele Sadelain, Isabelle Riviere, and Jae Park
Testing CRISPR-Edited CAR T Cell Therapy in Lymphoma Clinical Trial

A groundbreaking clinical trial is testing CAR T cells created using CRISPR gene-editing technology.
SKI biomedical engineer Dr. Daniel Heller
Getting Drugs Across the Blood-Brain Barrier Using Nanoparticles

Learn how MSK researchers are investigating the use of nanoparticles to carry drugs across the blood-brain barrier.
Melanie Steele, MPH, Director of Patient Financial Engagement at PFS
Making Cancer Treatment More Affordable: MSK Nurses Ensuring Access to Care

Memorial Sloan Kettering Cancer Center (MSK) is committed not only to providing exceptional cancer care but also to ensuring access to care for everyone who needs it. Unfortunately, some patients — often those whose insurance plan offers a very narrow provider network or those who are underinsured — have trouble shouldering the significant financial burden that can come with a cancer diagnosis. MSK has a special team in place to make sure these patients can still get the care they deserve.
A scientist holds a box of frozen samples
MSK Research Highlights, February 23, 2023

New research from MSK offers a window into patients’ complex decision-making around adjuvant therapy, explores the promise of engineered CAR T cells, highlights the success of a summer research program to support groups underrepresented in science, and more.
Q&A
Dr. Sergio Giralt
Improving Treatment for Recurrent Multiple Myeloma With Ide-Cel CAR T Therapy

In this Q&A, MSK hematologic oncologist Sergio Giralt, MD, talks about a phase 3 trial of ide-cel CAR T therapy for people with recurrent multiple myeloma and what it may mean for people with this hard-to-treat blood cancer.
woman getting vaccine from doctor
HPV Vaccine Age Limit: You Might Not Be Too Old — What You Should Know

Learn from MSK experts what people over 26 should know about getting the HPV vaccine to protect themselves from several forms of cancer.